advertisement
Abstract #8299 Published in IGR 4-3
Efficacy of brimonidine 0.2 per cent as adjunctive therapy to beta-blockers: a comparative study between POAG and CACG in Asian eyes
Ruangvaravate N; Kitnarong N; Metheetrairut A; Danwiriyakul WJournal of the Medical Association of Thailand 2002; 85: 894-900
OBJECTIVE: To compare the efficacy and safety profile of brimonidine as adjunctive therapy to beta-blockers between primary open-angle glaucoma (POAG) and chronic angle-closure glaucoma (CACG) in Asian eyes. DESIGN: Three-month, open-label, prospective study. PARTICIPANTS: Twenty-three patients (35 eyes) with POAG and 25 patients (39 eyes) with CACG were enrolled in the study. INTERVENTION: Patients with POAG or CACG post iridectomy whose IOP was inadequately controlled with topical beta-blocker monotherapy were included. Then, brimonidine 0.2% was added twice daily in both groups. Study visit occurred at weeks 2, 4, 8, and 12. Complete ophthalmic examinations were performed at all visits. MAIN OUTCOME MEASURES: Efficacy was determined by reduction in IOP from baseline and tolerability was assessed by reports of adverse events. RESULTS: After three months of brimonidine adjunctive treatment, the mean (± SEM) IOP reduction were 4.37 ± 0.34 mmHg (19.4%) in POAG and 4.54 ± 0.37 mmHg (20.1%) in CACG (p = 0.741). No serious ocular or systemic adverse event was reported. CONCLUSION: Brimonidine was well tolerated, efficacious and provided additive IOP reduction in POAG and CACG.
N. Ruangvaravate, MD, Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
